Skip to main content

Table 3 Univariable analyses of factors associated with 30-day mortality

From: Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status

 

HR (95% CI)

P value

Female gender

1.25 (0.83–1.87)

0.270

Age

1.00 (0.98–1.01)

0.898

Primary tumor site

 Cutaneous squamous-cell carcinoma

(reference)

 

 Gastrointestinal

1.32 (0.32–5.44)

0.693

 Breast

1.15 (0.26–5.01)

0.845

 Head and Neck

2.75 (0.53–14.23)

0.226

 Genitourinary

0.52 (0.07–3.69)

0.515

 Gynecologic

1.00 (0.18–5.48)

0.996

 Lung

0.92 (0.19–4.25)

0.915

 Sarcoma

0.87 (0.16–4.49)

0.871

 Unknown primary

0.90 (0.08–9.94)

0.933

 Number of metastatic sites (>  2 vs ≤ 2)

0.91 (0.66–1.35)

0.663

Main symptom at hospitalization

 Pain

(reference)

 

 Dyspnea

1.04 (0.50–2.17)

0.896

 Infection-related symptoms

1.14 (0.49–2.64)

0.753

 Bleeding/ Symptomatic anemia

0.53 (0.15–1.90)

0.336

 Gastrointestinal symptoms

2.04 (1.07–3.88)

0.029

 Neurologic symptoms

1.79 (0.67–4.78)

0.243

 Fatigue

1.79 (0.77–4.16)

0.171

ECOG-PS (3–4 vs 2)

2.05 (1.17–3.62)

0.012

Anemia (yes vs no)

1.05 (0.71–1.55)

0.792

Leukocytosis (yes vs no)

1.20 (0.80–1.79)

0.364

Lymphopenia (yes vs no)

1.07 (0.72–1.60)

0.710

Hypercalcemia (yes vs no)

2.09 (1.20–3.63)

0.008

Renal impairment (yes vs no)

1.20 (0.62–2.31)

0.573

Liver enzymes elevation (yes vs no)

1.84 (1.17–2.90)

0.008

Total bilirubin elevation (yes vs no)

3.07 (1.94–4.84)

< 0.001

Body mass index

 Underweight

(reference)

 

 Normal

1.07 (0.58–1.97)

0.810

 Overweight

1.09 (0.52–2.26)

0.817

 Obesity

1.25 (0.61–2.59)

0.531

Charlson Index > 6

1.27 (0.83–1.94)

0.253

  1. Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance Status, HR hazard ratio, CI confidence interval
  2. 1Univariable Cox regression